|
|
|
|
|
|
|
|
"Interim results from the PRECEDENT study, a randomized phase II study of the combination of EC145 and Doxil for the treatment of patients with platinum-resistant ovarian cancer, will be provided during an oral presentation. EC145 is a folate-targeted conjugate of a very potent chemotherapy drug."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.